Dr. Pillinger and his colleagues are conducting ongoing research into the link between gout, colchicine therapy and cardiovascular disease and, although the results are not ready, he noted that the trends they’re seeing in the interim data are promising.
You Might Also Like
- Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium
- Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium
- Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Explore This IssueApril 2014
Also By This Author
Kimberly J. Retzlaff is a medical journalist based in Denver.
- Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(9):237–241.
- Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare. Arthritis & Rheumatism. 2010;62(4):1060–1068.
- Schlesinger N, Mysler E, Lin H-Y, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–1271.
- Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatology. 2012;39(7):1458–1464.